Speakers:
– Ken Bradley, Global Head, Infectious Disease Discovery, Roche (Switzerland)
– Diarmaid Hughes, Professor of Medical Molecular Bacteriology, Uppsala University (Sweden)
Moderator:
– Karen Bush, Professor of Practice in Biotechnology, Emerita, Indiana University (USA)
Presentation 1: Progression criteria and Go/NoGo decisions in antibacterial drug discovery – an industry view (Ken Bradley)
– Drug discovery starts and ends with the patient.
– Target product profiles (TPPs) guide R&D.
– Target candidate profiles (TCPs) provide guidance and enable Go/NoGo decision making for preclinical programs.
– Examples will be provided to showcase decision making in preclinical research.
Presentation 2: Progression criteria and Go/NoGo decisions in antibacterial drug discovery – an academic view (Diarmaid Hughes)
– The academic research environment as it relates to antibiotic discovery.
– Serendipity versus planning in academic antibiotic discovery.
– The importance of projects like ENABLE in guiding academic researchers along the path to a useful drug.
This live webinar includes an interactive Q&A session.
Date and time:
Tue, Apr 9, 2024 2:30 PM – 4:00 PM CEST
Dedicated registration link here
